Last reviewed · How we verify
Nalcrom
At a glance
| Generic name | Nalcrom |
|---|---|
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia (PHASE1, PHASE2)
- Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer (PHASE2)
- PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS (PHASE2)
- Application of Ectoine Nasal Spray in Comparison With Cromolyn Sodium Containing Nasal Spray in Patients With Allergic Rhinitis
- Reverse Triple Negative Immune Resistant Breast Cancer (PHASE2)
- Novel Strategies for Reducing Burn Scar Itch (PHASE3)
- Cromoglicate in Psoriasis (PHASE2)
- Cromoglicate in Mastocytosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nalcrom CI brief — competitive landscape report
- Nalcrom updates RSS · CI watch RSS
- Universitaire Ziekenhuizen KU Leuven portfolio CI